产品详情
产品名称LGALS2 Antibody
来源种属Rabbit
克隆性Polyclonal
应用ELISA WB IHC
种属反应性Human;Mouse
特异性The antibody detects endogenous level of total LGALS2 protein.
免疫原类型Recombinant protein
免疫原描述Full length fusion protein
基因/蛋白名称LGALS2
标记Unconjugated
别名ectin, galactoside-binding, soluble, 2, HL14
数据库入口号Genbank No.: BC059782
Uniprot
BC059782
配方Supplied at 0.5mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.3, 0.05% sodium azide and 50% glycerol.
保存Store at -20˚C/1 year
应用详情
Predicted MW: 15kd
ELISA: 1:1000-1:5000
Western blotting: 1:200-1:1000
Immunohistochemistry: 1:10-1:50
Gel: 15%+12%SDS-PAGE
Lane1: Human liver Cancer tissue lysate
Lane2: Human leiomyosarcoma tissue lysate
Lysates: 40 ug per lane
Primary antibody: 1/250 dilution
Secondary antibody: Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution
Exposure time: 10 seconds
The image on the left is immunohistochemistry of paraffin-embedded Human brain cancer tissue using 31075 (LGALS2 Antibody) at dilution 1/13, on the right is treated with the fusion protein.
The protein encoded by this gene is a soluble beta-galactoside binding lectin. The encoded protein is found as a homodimer and can bind to lymphotoxin-alpha. A single nucleotide polymorphism in an intron of this gene can alter the transcriptional level of the protein, with a resultant increased risk of myocardial infarction. This protein binds beta-galactoside. Its physiological function is not yet known.
如果您使用该产品31075发表了文章，请通知我们，让我们可以引用您的文献。
et al,In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. In Sci Adv on 2022 Jul by Peng Ji, Yue Gong, et al..PMID:35767614
, (2022),
PMID:
35767614
有货
